Arrow
Arrow
Slider

Please find below the latest news from Premaitha Health. We also share this news across social media networks.

  • 16 February 2018 - Premaitha secures market entry into Egypt +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha secures market entry into Egypt

    Manchester, UK – 16 February 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces that it has signed an exclusive agreement (the “Agreement”) with a new partner (the “Partner”) to offer the IONA ® test across Egypt. As a result of the Agreement, the Company is pleased to have secured its first

    Read More
  • 6 February 2018 - Premaitha raises awareness of the IONA® test at key conferences in the Middle East +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha raises awareness of the IONA ® test at key conferences in the Middle East

    Manchester, UK – 6 February 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, announces it will be participating in key conferences in the Middle East to further raise the profile of the IONA ® test across this region.  

    Medlab Dubai

    Medlab is one of

    Read More
  • 5 February 2018 - Premaitha’s IONA® test approved for sale in Brazil +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha’s IONA ® test approved for sale in Brazil

    Manchester, UK – 5 February 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, announces that the IONA ® test has been approved by Brazil’s regulatory authority, Agência Nacional de Vigilância Sanitária (“ANVISA”), for sale as an in vitro diagnostic (“IVD”) test.  

    In September 2017, Premaitha announced that the Company’s IONA

    Read More
  • 29 December 2017 - Half Year Results +

    Premaitha Health PLC
    (“Premaitha”, the “Company” or the “Group”)

    Half year results

    Manchester, UK – 29 December 2017: Premaitha Health PLC (AIM: NIPT), a leading molecular diagnostics group with a primary focus on the commercialisation of its non-invasive prenatal testing (“NIPT”) technology, announces half year results for the six months ended 30 September 2017.

    Financial highlights
    •    Revenues increased by 87% to £2.7m (H1 2016/17: £1.5m)
    •    Test volumes doubled to over 22,000 (H1 2016/17:

    Read More
  • 11 December 2017 - Premaitha secures four further laboratories in Europe +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Premaitha secures four further laboratories in Europe

    Manchester, UK – 11 December 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), announces further expansion of its European customer base, with four new laboratories added.

    The laboratories are situated across three EU countries. The Company’s European distributors secured three of the laboratories, with one laboratory having been contracted directly by

    Read More
  • 01 December 2017 - Premaitha CEO Wins Bionow Outstanding Contribution Award +

    Premaitha CEO Wins Bionow Outstanding Contribution Award

    Steve Little

    Manchester, UK – 1 December 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), is proud to announce that its CEO, Dr Stephen Little, last night received Bionow’s Outstanding Contribution award in recognition of his “significant contribution to the biomedical sector.”

    Bionow is an organisation which supports business growth, competitiveness and innovation within the biomedical and life science sectors

    Read More
  • 27 November 2017 - Middle East laboratory network expansion +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Middle East laboratory network expansion

    Manchester, UK – 27 November 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), announces further expansion of its Middle Eastern customer base, with four new laboratories having been signed up in the region.

    Premaitha’s Middle Eastern distributors have secured four new laboratories seeking to offer the IONA ® test to their respective population

    Read More
  • 23 November 2017 - Premaitha signs new partner to offer NIPT solution in East Asia +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha signs new partner to offer NIPT solution in East Asia

    Manchester, UK – 23 November 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces that it has signed an agreement with a new laboratory partner (the “Partner”) to offer an NIPT screening solution in a new East Asian territory (the “Territory”) for Premaitha.  

    The Partner is

    Read More
  • 21 November 2017 - Litigation First Instance Judgment +

    Premaitha Health plc
    (“Premaitha” or the “Company” or the “Group”)

    Litigation First Instance Judgment

    Manchester, UK – 21 November 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces details of a legal judgment handed down today.

    The UK High Court has today delivered its first instance judgment (the Judgment) in relation to the ongoing dispute with Illumina Inc and others concerning three UK patent families,

    Read More
  • 13 October 2017 - Commercial progress in the Middle East +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Commercial progress in the Middle East

    Manchester, UK – 13 October 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), announces further commercial progress in the Middle East, where several new contracts have been signed via the Company’s regional distribution network.

    Premaitha has secured contracts with three additional laboratories in the region including in the UAE and Saudi Arabia,

    Read More
  • 29 September 2017 - Full year results to 31 March 2017 and half-year trading update +

    Issued on behalf of Premaitha Health plc
    Manchester, UK: Friday, 29 Sept 2017

    Premaitha Health PLC
    (“Premaitha,” the “Company” or the “Group”)

    Full year results to 31 March 2017 and half-year trading update

    Manchester, UK – 29 September 2017: Premaitha (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces its full year results for the twelve months ended 31 March 2017; and provides an update on trading performance in

    Read More
  • 19 September 2017 - Premaitha to offer NIPT in South Africa +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Premaitha to offer NIPT in South Africa

    Manchester, UK – 19 September 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing, announces that it has signed an agreement with Ampath group, practising as Drs Du Buisson, Kramer, Swart, Bouwer Inc. (“Ampath”) to offer the Company’s IONA ® test in South Africa, where the Company has appointed Barker Medical Pty Ltd

    Read More
  • 7 September 2017 - Further patent infringement claims received from Illumina & Sequenom +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Further patent infringement claims received from Illumina & Sequenom

    Manchester, UK – 7 September 2017: Premaitha Health plc (AIM: NIPT) announces that it has today received notification from Illumina and Sequenom that a further claim for patent infringement has been filed in the High Court of Justice in London.

    Premaitha is a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”) and has been robustly defending

    Read More
  • 29 August 2017 - Premaitha approved for Good Manufacturing Practice by ANVISA Brazil +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha approved for Good Manufacturing Practice by ANVISA Brazil

    Manchester, UK – 29 August 2017: Premaitha Health plc (AIM: NIPT) announces that it has been approved for Brazilian Good Manufacturing Practice (“B-GMP”) for the Company’s IONA ® test by Brazil’s regulatory authority, the Agência Nacional de Vigilância Sanitária (“ANVISA”).

    Premaitha is a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”). The B-GMP approval enables Premaitha

    Read More
  • 12 July 2017 - Investment Agreement Extension with Thermo Fisher Scientific +

    Premaitha Health Plc
    (“Premaitha”, the “Company” or the “Group”)

    Investment Agreement Extension with Thermo Fisher Scientific

    Manchester, UK – 12 July 2017 - Premaitha Health Plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing, is pleased to announce that it has entered into a further extension of the investment agreement with Thermo Fisher Scientific (“Thermo Fisher”) announced on 14 December 2015 and extended as announced on 23 September 2016, further developing

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
Pregnant lady sitting at table with Laptop

Investor Relations
Ben Simons / Fiona Henson
Vigo Communications
180 Piccadilly
London W1J 9HF
premaitha@vigocomms.com
T : +44 (0) 20 7830 9700

Two business people looking at computer screen